Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
Nazionalità Coordinatore | France [FR] |
Sito del progetto | http://www.medall-fp7.eu |
Totale costo | 15˙659˙041 € |
EC contributo | 11˙990˙939 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2010-single-stage |
Funding Scheme | CP-IP |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-12-01 - 2015-05-31 |
# | ||||
---|---|---|---|---|
1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | coordinator | 658˙597.20 |
2 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 1˙896˙840.00 |
3 |
FUNDACIO CENTRE DE RECERCA EN EPIDEMIOLOGIA AMBIENTAL - CREAL
Organization address
address: Calle Doctor Aiguader 88 contact info |
ES (BARCELONA) | participant | 1˙493˙456.00 |
4 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 1˙380˙930.00 |
5 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 823˙681.00 |
6 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 746˙461.60 |
7 |
SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Organization address
address: Promenade 35 contact info |
CH (DAVOS PLATZ) | participant | 729˙630.40 |
8 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 613˙643.00 |
9 |
BIOMAX INFORMATICS AG
Organization address
address: ROBERT KOCH STRASSE 2 contact info |
DE (PLANEGG) | participant | 597˙365.00 |
10 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 568˙260.25 |
11 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 517˙553.00 |
12 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 341˙550.00 |
13 |
UNIVERSITEIT UTRECHT
Organization address
address: Heidelberglaan 8 contact info |
NL (UTRECHT) | participant | 292˙051.00 |
14 |
UNIVERSITETET I OSLO
Organization address
address: Problemveien 5-7 contact info |
NO (OSLO) | participant | 287˙095.00 |
15 |
BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST
Organization address
address: Duckworth Lane contact info |
UK (Bradford) | participant | 249˙846.30 |
16 |
"onmedic Networks, S.L"
Organization address
address: Balmes 30 contact info |
ES (Barcelona) | participant | 194˙153.40 |
17 |
Nome Ente NON disponibile
Organization address
address: STENBACKINKATU 9 contact info |
FI (HELSINKI) | participant | 183˙086.40 |
18 |
AZIENDA SANITARIA LOCALE ROMA
Organization address
address: Borgo Santo Spirito 3 contact info |
IT (ROMA) | participant | 174˙999.60 |
19 |
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING
Organization address
city: Brussels contact info |
BE (Brussels) | participant | 77˙840.25 |
20 |
UNIVERSYTET MEDYCZNY W LODZI.
Organization address
address: Al. Kosciuszki, 4 contact info |
PL (LODZ) | participant | 59˙399.60 |
21 |
ODENSE UNIVERSITETSHOSPITAL
Organization address
address: Sdr. Boulevard 29 contact info |
DK (ODENSE) | participant | 55˙000.00 |
22 |
BIOMAY AG
Organization address
address: LAZARETTGASSE 19 contact info |
AT (WIEN) | participant | 49˙500.00 |
23 |
Arizona Board of Regents
Organization address
address: S. Rural Road 1711 contact info |
US (Tempe) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Causes explaining the epidemic of IgE-associated (allergic) diseases are unclear. MeDALL (Mechanisms of the Development of Allergy) aims at generating novel knowledge on mechanisms of allergy initiation, in particular in childhood. To understand how a complex network of genetic and environmental factors leads to complex allergic phenotypes, a novel stepwise, large and integrative translational approach is needed. MeDALL includes experts in allergy, epidemiology, genetics, immunology, biology, animal models, biochemistry and systems biology combining strengths of ongoing EU projects. Classical phenotypes (expert-based) and novel phenotypes of allergy (hypothesis-free statistical modelling) are compared. Population-based data are collected from a cross-sectional study (Karelia) and existing birth-cohorts followed using a common protocol. IgE to foods and inhalants are tested using component-resolved diagnosis across Europe in populations. Biomarker profiles (“fingerprints”) are extensively assessed using epigenetics, targeted proteomics and unbiased transcriptomics in a subsample of the study population. Those associated with allergic phenotypes are validated in large study populations. Relevant fingerprints are combined into network biomarker phenotype “handprints” using a systems biology approach and validated in a sufficiently powered sample. Animal studies and in vitro human immunology reinforce the validation. This information coupled with classical and novel phenotypes characterize environmental protective and susceptibility factors of allergy and risk groups. Results are fitted into new integrative complex mathematical models to establish suitable biomarkers for early diagnosis, prevention and targets for therapy of allergy-associated diseases such as asthma and atopic dermatitis. Ethics and gender are considered. MeDALL aims at improving health of European citizens, Europe competitiveness and innovative capacity while addressing global health issues.'
Understanding how allergies develop is key for prevention and therapy. A large European study is working to unravel the complex network of genetic and environmental factors implicated in allergy development during childhood.
Improving health services for European citizens with dementia: Development of best practice strategies for the transition from ambulatory to institutional long-term care facilities
Read MoreEarly warning signals of ageing in human stem cells and age-related disorders
Read More